



CLAIMS

A method of treating a patient having a multidrug-resistant meoplasm, said method comprising the step of inhibiting membrane transport mediated by the multidrug resistance protein MRP by administering an effective amount of a compound of Formula I

$$R_1$$
 R_2
 $O-(CH_2)_n-O-A$
 R_4
 R_3

10

wherein R_1 is

15

Y is hydrogen or halo;

 R_2 is hydrogen, -OH, or -O $\not\subset H_3$;

 R_3 is C_1 - C_6 alkyl;

20 R₄ is hydrogen, -OH, or -OCH₃;

n is 3, 4, or 5;

A is

$$R_6$$
 or R_7 R_5

25

 R_5 is hydrogen, C_1 - C_6 alkyl, C_2 - C_5 alkenyl, C_2 - C_5 alkynyl, benzyl, or phenyl; R_6 is hydrogen or hal ϕ ;

30 R₇ is -COOH or 5-tetrazolyl;

T is a bond, $-CH_2$ -, $-\Phi$ -, -C(=O)-, or $-S(O)_q$ -; and q is 0, 1, or 2;



-72-

provided when one of R_2 and R_4 is -OH or -OCH₃, the other of R_2 and R_4 must be hydrogen, or a pharmaceutically acceptable base addition salt or solvate thereof.

2. The method of claim 1 wherein the compound is administered at a concentration of about 0.5 to about 50 mg/kg body weight of the patient.

5